Message #36 From:
Stock News Bot Date: December 14, 2006 05:09:00 AM
CLRI News Clearant Announces Second Agreement to Expand Its Direct Distribution Growth Initiative (R) for the Sports Medicine Market
LOS ANGELES--(BUSINESS WIRE)--Clearant, Inc. (OCTCBB:CLRI) announced today that it signed an agreement
with JPS Surgical, Inc., a leading distributor of orthopedic surgical
supplies, to represent and distribute Clearant Process®
Sterile Implants for allograft sport medicine surgeries. Under the terms
of the agreement, JPS Surgical, Inc. will deploy its team of 20 sales
representatives to market the implants to the sports medicine
specialists throughout the states of Oklahoma and Arkansas.
“This is the second distribution agreement
that we announce this month to expand our reach to surgeons in a region
where Clearant does not have a direct sales force, reflecting; the
growing demand for Clearant Process sterile implants by surgeons and
distributors. To-date, Clearant does not have any sales representation
in the states of Arkansas and Oklahoma. As a result, we are pleased to
be able to complement our direct distribution initiative with a group of
sales people as successful as those of JPS Surgical, Inc. This agreement
will, immediately, give Clearant greater market reach in the states of
Oklahoma and Arkansas and we are confident that this will lead to faster
adoption for the Clearant Process sterile sports medicine implants in
that region,” said Clearant Chief Executive
Officer Alain Delongchamp.
“Each one of our 20 sales representatives has
a relationship with surgeons from every orthopedic sub-specialty,
including sports medicine, arthroplasty and trauma in their individual
territory thanks to our very broad product line. As our sales
representatives are working with a large number of the hospital staff
and orthopedic surgeons in our region, we are seeing a significant
demand for safer tissue,.” said Mark Farrow,
President JPS Surgical, Inc. “Over the last
couple of weeks, we received several orders for the Clearant Process
implants from surgeons we have a relationship with.. We expect that a
substantial number of the surgeons we work with will become regular
users of Clearant Process implants in the near term.”
Over the past two years, Clearant Process®
Sterile Implants have achieved recognition and support in the sports
medicine field due to their excellent performance and superior
protection against infection. To-date, more than 9,000 patients received
a Clearant Process sterile implant with success.
The Clearant Process is the first technology capable of eliminating all
types of pathogens in tissue implant sterilized in its final packaging,
while maintaining the integrity of the essential underlying protein in
the tissue. Products processed with the Clearant Process can achieve,
and even exceed, levels of sterility associated with medical devices
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process,
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the
underlying tissue implant or protein. The Company began to distribute
directly to surgeons, hospitals and clinics Clearant Process sterile
implants in June 2006; in addition, Clearant continues to license the
Clearant Process and provides its patented sterilization services to
tissue banks and other biological products manufacturers. As of the end
of 1Q 2006, Clearant had 10 license and service agreements with tissue
banks. To date more than 9,000 patients have been successfully implanted
with Clearant Process sterile implants supplied by one of the Company's
licensed partners. Whereas various competing sterilization methods only
kill specific types of pathogens (such as bacteria or lipid-enveloped
viruses) for specific products, the Clearant Process reduces all types
of pathogens for products across many market segments including tissue
implants, plasma proteins, recombinant products, medical devices and
blood products. Also, the Clearant Process can be applied at various
stages of product processing and/or manufacturing, including in the
final packaging. For more information, please visit www.clearant.com.
About O.R. Specialties -
JPS Surgical, Inc. provides both surgical and post surgical products to
hospitals, surgery centers, doctor's offices, rehab providers, and
podiatrist offices. Our headquarters are in Tulsa, Oklahoma. Our
surgical division is made up of tenured professional consultants that
specialize in orthopedic sports medicine, trauma, joint replacement, and
podiatric surgical procedures.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the Safe
Harbor provisions of the Private Securities Litigation Reform Act of
1995, in particular statements regarding surgeons strongly recommending
the use of implants with tissue treated by the CLEARANT PROCESS, and the
conclusions from a study by surgeons to build demand for sterilized
tissue.These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of
which are beyond the company's control, which may cause actual results
to differ materially from stated expectations. These risk factors
include, among others, limited operating history, difficulty in
developing, exploiting and protecting proprietary technologies, results
of additional clinical studies, acceptance and success of our direct
distribution of allografts, efficacy of the technology, intense
competition and substantial regulation in the biotechnology industry,
and additional risks discussed in the company's filings with the SEC,
available on the SEC web site http://www.sec.gov.
